Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 5Psoriasis 4Lymphoma, Follicular 2Leukemia, Myelomonocytic, Juvenile 2Wilms Tumor 1Stomatitis 1Spondylitis, Ankylosing 1Respiratory Distress Syndrome 1Recurrence 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Plaque, Amyloid 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms 1Melanoma 1Lupus Nephritis 1Lung Injury 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Inflammation 1Diabetes Mellitus, Type 1 1Dermatomyositis 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1Bronchiolitis Obliterans 1Blast Crisis 1

Interventions

canakinumab 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Arthritis, Juvenile × Etanercept × Clear all
NCT03780959 2019-08-02

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Amgen

Phase 2/3 Completed
69 enrolled 11 charts

Arthritis, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡